Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 1/20 | 0.52 |
| ▸ | ATP4B | P51164 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | QPCT | Q16769 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6033167 | 0.92 | LTA4H (0.45) | ATP4AATP4BCYP19A1KMT2AMAPT | |
| SCHEMBL13201562 | 0.87 | ATP4A (0.53) | ATP4AATP4BCYP19A1KDM4ELMNA | |
| SCHEMBL14189706 | 0.85 | ATP4A (0.52) | ATP4AATP4BCYP19A1KMT2AMEN1 | |
| SCHEMBL22397927 | 0.84 | MEN1 (0.55) | ATP4AATP4BCYP19A1KMT2AMAPT | |
| SCHEMBL5046643 | 0.84 | ATP4A (0.52) | ATP4AATP4BCYP19A1KMT2AMAPT | |
| SCHEMBL765017 | 0.84 | QPCT (0.56) | ATP4AATP4BCYP19A1KMT2AMAPT | |
| SCHEMBL18837867 | 0.84 | ATP4A (0.52) | ATP4AATP4BCYP19A1KMT2AMAPT | |
| SCHEMBL14996228 | 0.82 | ATP4A (0.53) | ATP4AATP4BCYP19A1KMT2AMAPT | |
| SCHEMBL5566302 | 0.81 | TBXAS1 (0.55) | ATP4AATP4BCYP19A1KMT2AALDH1A1 | |
| SCHEMBL16417747 | 0.81 | MEN1 (0.59) | ATP4AATP4BCYP19A1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622896-B1 | NOVEL ANILINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2007-07-04 | — | — | EP | claimed |
| US-7205326-B2 | Aniline derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-17 | — | — | US | claimed |
| EP-1622896-A1 | NOVEL ANILINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-08 | — | — | EP | claimed |
| US-20040254217-A1 | Aniline derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2004-12-16 | — | — | US | claimed |
| WO-2004096796-A1 | NOVEL ANILINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-11 | — | — | WO | claimed |
| EP-1732543-B1 | TETRACYCLIC CARBOLINE DERATIVES FOR INHIBITING ANGIOGENESIS | PTC THERAPEUTICS INC (US) | 2017-05-10 | — | — | EP | disclosed |
| CN-100345845-C | Aniline derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2007-10-31 | — | — | CN | disclosed |
| EP-1622896-B1 | NOVEL ANILINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2007-07-04 | — | — | EP | disclosed |
| US-7205326-B2 | Aniline derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-17 | — | — | US | disclosed |
| CN-1780830-A | Aniline derivatives, process for their preparation and their use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2006-05-31 | — | — | CN | disclosed |
| EP-1622896-A1 | NOVEL ANILINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-08 | — | — | EP | disclosed |
| US-20040254217-A1 | Aniline derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2004-12-16 | — | — | US | disclosed |
| WO-2004096796-A1 | NOVEL ANILINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254217-A1 | Aniline derivatives, their manufacture and use as pharmaceutical agents | ERBB2, EGFR, ERBB3 | ATP4A 3959/4885ATP4B 4542/4885CYP19A1 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.